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Abstract 
In breast cancer (BC), the prognostic value of Ki67 expression is well-documented. 
Intratumoural heterogeneity (ITH) of Ki67 expression is amongst the several technical 
issues behind the lag of its inclusion into BC prognostic work-up. The 
immunohistochemical (IHC) expression of anti-Ki67 antibody (MIB1 clone) was 
assessed in four full-face (FF) sections from different primary tumour quadrants and 
their matched axillary nodal (LN) metastases in a series of 55 BC.  Assessment was 
made using the highest expression (hot) spots (HS), lowest expression (LS), and 
overall/average expression scores (AS) in each section. Heterogeneity score (Hes), co-
efficient of variation and correlation coefficient were used to assess the levels of Ki67 
ITH. Ki67 HS, LS, and AS scores were highly variable within the same section and 
between different sections of the primary tumour, with maximal variation observed in 
the LS (p<0.001). The least variability between the different slides was observed with 
HS scoring. Although the associations between Ki67 and clinicopathological and 
molecular variables were similar when using HS or AS, the best correlation between AS 
and HS was observed in tumours with high Ki67 expression only. Ki67 expression in LN 
deposits was less heterogeneous than in the primary tumours and was perfectly 
correlated with the HS Ki67 expression in the primary tumour sections (r=0.98, p 
<0.001). In summary, assessment of Ki67 expression using HS scoring method on a full-
face BC tissue section can represent the primary tumour growth fraction that likely to 
metastasise. The association between Ki67 expression pattern in the LN metastasis and 
the HS in the primary tumour may reflect the temporal heterogeneity through clonal 
expansion.  
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Introduction 
Immunohistochemical (IHC) detection of proliferation associated antigens have long 
been studied in breast as well as other cancers [1]. Ki67 is a labile non-histone nuclear 
protein of approximately 395 kDa, amount of which is tightly regulated during cell 
cycle. [2-4] Detailed cell cycle analysis revealed its presence in the nuclei of cells in all 
active cycling/proliferative phases, while quiescent/resting cells do not express it. 
Therefore, it has been used as a biomarker to assay the growth fraction of a given cell 
population [1, 5]. Nuclear positivity of Ki67 protein is an indication of cell 
proliferation[6, 7] and it has long been reported as a prognostic marker in breast cancer 
(BC) [8-11]. There is evidence that tumours with higher expression levels of Ki67 
respond better to adjuvant chemotherapy than those tumour having low levels of Ki67 
[11, 12]. Ki67 expression is an independent predictive of neoadjuvant chemotherapy in 
BC patients [13, 14]. as well as the neoadjuvant endocrine therapy in postmenopausal 
patients.[15] Patients with high post-treatment Ki67 expression levels have a higher 
risk for disease relapse and death than those with low or intermediate Ki67 expression 
[16]. 
Ki67 is used to provide additional useful prognostic information in BC: 1) to define the 
intrinsic molecular subtypes immunohistochemically [17, 18], 2) as a component in the 
prognostic multigene signatures including Oncotype DX [19] and IHC4 [20, 21], and 3) 
prognostically stratify grade 2 tumours [22] and accurately reflect tumour proliferative 
status in poorly fixed specimens. However, biological heterogeneity of Ki67 expression 
is a well-documented phenomenon visible across specimens from the same tumour. 
Such heterogeneity could be a gradient of increasing Ki67 positivity toward the tumour 
edge and or Ki67 variable expressivity anywhere in the tumour in the form of hot spots 
[23, 24]. To ensure satisfactory reproducibility when using Ki67 IHC in research 
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purposes and in the way of it inclusion into routine clinical practice for BC, it is still 
debatable whether to score the hot spots of expression or the average expression. The 
International Ki67 in Breast Cancer working group recommends scoring Ki67 as the 
average score of positive nuclei in the invasive tumour. This was based on the lack of 
sufficient evidence to use the “hot spot” of expression [24]. Moreover, many of the 
previous Ki67 prognostic studies have used tissue microarray [25, 26], which may not 
represent the proliferative status of the whole at individual patients level. In this study, 
Ki67 expression was assessed on full-face sections from different primary tumour 
quadrants of surgical specimens as well as from the corresponding axillary nodal 
metastasis. A systematic approach of staining assessment was followed to assess the 
impact of intratumoural heterogeneity of Ki67 expression in the same section as well as 
different sections from multiple primary tumour blocks and corresponding nodal 
metastatic deposits.      
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Materials and methods:  
In this study, four different primary tumour quadrants from 55 primary operable 
invasive breast carcinomas and sections from the corresponding axillary nodal 
metastases were used to assess Ki67 expression. This subset of cases is from the 
Nottingham primary series of early invasive BC series from patients presented to 
Nottingham City Hospital from 1995-1998 and managed according to a uniform 
protocol. Cases were chosen based on the availability of four tumour blocks per tumour. 
Tumours in these patients were 5 cm in diameter or less at time of presentation [27]. 
Patients’ clinical and pathological data including age, histological tumour type, primary 
tumour size, lymph node status, histological status, Nottingham prognostic index (NPI), 
and vascular invasion were available and prospectively maintained [28-30]. This study 
was approved by Nottingham Research Ethics Committee 2 under the title of 
‘‘Development of a molecular genetic classification of breast cancer’’. 
Immunohistochemistry: 
Form each Formalin-fixed paraffin embedded tissue block, 4 μm thick full-face tissue 
sections were cut and mounted on Superfrost slides (Surigpath). The 
immunohistochemical (IHC) expression of Ki67 was determined using MIB1 antibody 
(MIB1 clone, M7240, DAKO, Denmark) and the Novolink™ Max Polymer Detection 
System from Leica Biosystems (Leica Biosystems, RE7150-K, Leica, Newcastle, UK). 
Heat induced retrieval of antigen epitopes was performed in citrate buffer (pH 6) using 
microwave for 20 minutes, followed by immediate cooling. MIB1 primary antibody 
diluted as 1:100 in Leica antibody diluent (RE7133) was incubated for 60 min at room 
temperature. As per manufacturer’s guidelines, 3-3’ Diam-inobenzidine 
tetrahydrochloride (Novolink DAB substrate buffer plus) was freshly prepared and used 
as a chromogen. Sections were counterstained with Mayer’s haematoxylin for 6 min. 
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Negative (primary antibody replaced by phosphate-buffered saline) and positive 
controls (human tonsil sections) were included in each staining run to ensure 
reproducibility. Slides were dehydrated in alcohol, cleared in xylene and mounted with 
DPX.  
Ki67 scoring:  
Ki67 stained FF sections from different tumour quadrants and the matched axillary 
metastasis in lymph node (LN) positive cases were assessed following the Highest Score 
(HS = Hot-Spot), Lowest Score (LS), and Average Score/overall (AS) approach. Each 
section was first scanned at low-power light microscopic examination to identify area of 
HS and LS. As per our previous report, the HS was assessed in 1000 malignant invasive 
BC cells within the areas of hot spot staining at high power magnification (400×) [12]. 
The LS reflected the Ki67 score in the area of least number of positively stained 
malignant nuclei. The AS was the overall Ki67 scoring within the whole FF section 
taking into account all areas of tumour positive expression. The HS, AS, and LS were 
expressed as percent of Ki67-positive tumour cells divided by the total number of 
tumour cells within the assessed tumour area of invasive tumour. For each section, 
heterogeneity Score (HeS) was calculated as the difference between HS and LS (HeS = 
HS-LS). In all these scoring approaches, only nuclear staining in invasive tumours cells 
irrespective of its intensity was considered positive.  
Statistical analysis 
The statistical analysis was performed using Statistical Package for Social Sciences SPSS 
version 21 for Windows (Chicago, IL, USA). Co-efficient of variation (cvar), HeS, and 
Spearman rank correlation co-efficient were used to assess the ITH of Ki67 expression 
within the same section, between different quadrants from the same case, and between 
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the primary tumour and LN metastases. A p value of less than 0.05 (two-tailed) was 
considered significant.   
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Results:  
In the current study, the median patients’ age at diagnosis of this cohort was 52 years 
(range 30–70 years), with up to 53% of patients postmenopausal. The vast majority of 
cases were grade 2 and 3 (95%). Of all tumours, 35/55 cases (63.6%) were ductal 
carcinoma no special type (ductal/NST), with the remainder consisting of invasive 
lobular and mixed carcinomas.  ER positive tumours constituted (69.1%), while 13 
cases (24.1%) were HER2 positive (based on IHC and HER2 gene amplification 
detection using CISH).  Supplementary Table 1 summarises patient demographics and 
clinicopathological criteria of their tumours. 
Within the studied sections, Ki67 showed highly variable expression. Figure 1 depicts 
the LS and HS in different microscopic fields of two different BC cases. The Ki67 scores 
within the same section and in sections from different tumour quadrants in this series 
ranged from 0 to 100%. However, Ki67 staining within the metastatic deposits was 
more or less homogenously distributed and the AS ranged from 10-95%.   
To assess the level of heterogeneity, HeS was calculated for each section from each 
quadrant. Table 1 shows the ranges, mean, and median of HeS for each of the sections 
from different tumour quadrants of the studied series. The median HeS (i.e. the 
difference between the HS and LS in each section) for each quadrant was: 1, 2, 3 and 4 
was 25, 20, 20, and 25, respectively. The intra-slide HeS scores were significantly higher 
in cases with NST histology than invasive lobular and mixed cases (ANOVA, F = 
P<0.001) denoting higher Ki67 HS expression. However, the inter-slide HeS scores were 
significantly less variable in NST than the other two histologic variants, Figure 2.   
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The co-efficient of variation (CVAR) between Ki67 HS, LS, and AS within the same 
section (intra-slide scores) ranged from 13-96%. These figures demonstrated wide 
range of spatial heterogeneity of Ki67 expression within the same section of each 
tumour quadrant. To study the level of variability between HS, AS, and LS in different 
quadrants (inter-slide scores), the CVAR showed the least variability between the HS in 
different quadrants while the AS and LS showed higher variability, Figure 3. Levene’s F 
test for homogeneity of variance showed statistically significant differences between 
CVAR of HS, AS, and LS in the four studied quadrants from each case (F= 6.639, P = 
0.002). Tukey post-hoc analysis test showed that the CVAR of the HS were not 
statistically significant from those of the AS for the four quadrants studied (P = 0.835), 
while CVAR of the LS were significantly different from those of HS (P = 0.002) and AS (P 
= 0.014), Table 2. 
We proceeded to study the differences between Ki67 AS and HS and tested their 
statistical associations as continuous variables with the standard prognostic 
parameters. Statistically significant associations were observed between the HS and 
tumour grade, mitotic scores, nuclear pleomorphism, histologic tumour type, ER status, 
PR Status, HER2 status, and BC molecular subtype as previously defined [28], more than 
with the Ki67 AS. However, no significant associations were observed between Ki67 AS 
or HS and menopausal status, tumour size, axillary nodal stage, NPI classes, or 
lymphovascular invasion (LVI; Table 3)  
Because Ki67 is often dichotomised into a categorical variable, Ki67 AS and HS scores 
were categorised into low and high at 14% cut-off point. At this cut-off, cases tended to 
be classified as low proliferative with the AS relative to the HS within the same section. 
Table 3 displays the Ki67 AS and HS as classified into low and high at 14%, Table 4.   
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Ki67 staining within the metastatic deposits in axillary nodes was more or less 
homogenously distributed and the Ki67 expression ranged from 10-95%.  Spearman 
rank correlation co-efficient of Ki67 expression of metastatic deposits in the studied LN 
sections showed significant positive correlation with Ki67 expression in the studied 
primary tumour sections. Although the AS was significantly correlated with Ki67, the 
strongest correlation (r=0.98, p<0.001) was observed with the HS of the primary 
tumour, Figures 4. 
Univariate survival analysis of categorised Ki67 scores showed similar associations 
between Ki67 HS at 10% and 14% cut-offs and outcome in the different FF sections of 
the primary tumours and this was comparable to the associations obtained with mitotic 
scores.    
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Discussion:  
The proliferative marker Ki67 is a molecular maker with documented prognostic 
utilities in BC singly and in combinations with other markers [31]. Because only cycling 
cells express it [32], its heterogeneous distribution in invasive BC is anticipated. Highly 
proliferating tumours are likely to behave more aggressively but respond better to 
cytotoxic chemotherapy compared to low proliferating tumours [33]. However, the 
behaviour and response to antimitotic drugs of high and low proliferating clones within 
the same tumour remain unclear. In BC it is common to see higher proportions of Ki67 
positive cells at the periphery of the tumour denoting higher proliferation rates with areas 
more proliferative than others leading to the appearance of HS. Tumour areas in between HS 
show lower proliferative activity whilst lowest proliferative areas are called LS. Assessment 
of the overall Ki67 expression including HS and LS and areas in between is called average 
score. Currently no consensus for Ki67 staining evaluation whether it should only consider 
the HS if present, take the average score including HS or avoiding them completely [23] and 
comparable study assessing different scoring methods is needed.  
In this study, we used the validated MIB1 as anti-Ki67 monoclonal antibody, 
recommended as being the gold standard for its enhanced specificity [24], to assess the 
pattern of expression of Ki67 in a subset of BC using full-face sections from different 
primary tumour quadrants. This was primarily to test for spatial intratumoural 
heterogeneity (ITH) and its impact Ki67 assessment. In addition, matching cases with 
positive nodal metastasis were assessed as an endpoint to assess metastatic tumour cell 
clones. In each of the stained sections, expression was assessed in the HS, LS, and the AS.  
Within the studied cases, highly variable Ki67 expression was evident within the same 
section as well as in sections from multiple tumour quadrants representing spatial 
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zones in the primary tumour. Nevertheless, within the nodal metastatic deposits, 
staining showed homogenous distribution and was more towards the high proliferative 
side. Highly variable Ki67 expression was evident, both visually and statistically as per 
the co-efficient of variations results, within the same section; the intra-slide scores, as 
well as in sections from multiple tumour quadrants, the inter-slide scores, representing 
spatial zones in the primary tumour. Interestingly, inter-slide differences of AS, and LS 
were statistically significant in the four quadrants from each case, while the HS were not 
significantly different. Moreover, pairwise differences revealed that the LS were 
significantly different from those of HS and AS, while the latter were not different from 
each other. This latter finding underscores the impact of sampling on the final status of 
Ki67 being high or low. For instance, some studies reported on Ki67 prognostic 
significance were conducted on tissue microarrays (TMA) [34, 35]. TMA randomly 
punches out tiny cores, typically 0.6mm, which could hit low proliferative areas, 
yielding a low Ki67 status in an otherwise high proliferative case. Although TMAs are 
primarily a research tool conducted on large number of patients in population-based 
studies, this sampling error is usually balanced for by the large number of study 
population giving an overall prognostic significance [36, 37]. However, generalising cut-
offs demarcating low from highly proliferative cases generated in studies using TMA 
carries the potential of misclassification of some patients from high to low proliferative 
subgroups [38]. However, at an individual patient level, which is the case in clinical 
decision making for neoadjuvant therapy using core needle biopsy (CNB), again 
sampling bias or error could influence the final status of the case, as shown in our study. 
Fair agreement for Ki67 assessment between CNB and surgical specimen has been 
reported [39], denoting that the former may not truly representing the biologic profile 
of the tumour. Accordingly, specimen specific cut-off point (s) is to be considered. For 
13 
instance, when using preoperative CNB or when translating data from TMA-based 
research studies to potential clinical uses. 
To assess whether the Ki67 HS and AH could be interchangeably used, their 
associations, as continuous variables, with other BC prognostic and molecular 
parameters more significant associations were observed of the former than the latter. In 
this study, using different cut-offs, cases tended to be misclassified as low proliferative 
with the AS relative to the HS within the same section. Taken together, the HS was more 
representative of tumour proliferative status than the AS; results consistent with other 
reports using single FF section [40]. 
Within the nodal metastatic BC cells deposits, Ki67 staining showed homogenous 
distribution and was more towards the high proliferative side. Also, near perfect 
significant direct correlation was observed between Ki67 HS of the primary tumour and 
Ki67 score in metastatic nodal deposits. It was observed that the cells within the nodal 
deposits were highly proliferative and coincided with the HS of the primary tumour. As 
metastatic spread develops over time with natural selection of more aggressive clones 
[41], our findings could represent a further supporting evidence to endorse the Ki67 HS 
scoring approach as they are more representative of the metastatic clones.  
We have previously reported on prognostic utility of Ki67 in a large series of BC [12, 
42]. However, in this cohort, survival analyses showed shorter outcomes in patients 
with high Ki67 HS in the different sections from the primary tumour, yet the differences 
did not reach statistical significance. This could be attributed to the relatively limited 
numbers of patients when sub-grouped into low and highly proliferative. This is 
supported which is supported using mitotic scores of the same set yielded the same 
results.    
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Conclusions: In this study, the spatial heterogeneity of Ki67 expression in invasive BC 
was evident within at intra-slide as well as inter-slide levels using full-face sections 
from the primary tumours. The high Ki67 within LN metastasis corresponded to highest 
primary tumour expression reflecting tumour heterogeneity during metastatic process 
through clonal expansion. Therefore, the HS/hot spot scoring in full-face sections is 
more representative of the primary breast cancer growth fraction.   
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Figure legends:  
 
Figure 1: IHC expression of Ki67; A and B: LS and HS in an invasive BC in different fields 
of the same section. C and D another example of LS and HS of the same BC in different 
fields of the same section.  
 
 
Figure 2: median Heterogeneity scores (Hes) scores in multiple primary tumour 
quadrants in histologic tumour types (no special type NST, mixed types, and lobular 
carcinomas).   
  
 
Figure 3: Box plots for coefficient of variation of Ki67 HS, AS, and LS scores in multiple 
tumour quadrants. HS: Hotspot score, AS: average score, LS: lowest score.   
 
 
 
Figure 4: IHC expression of Ki67 in the primary tumour and LN metastatic deposits: A)  
LS, B) HS of the primary tumour, C) Ki67 expression in metastatic axillary nodal 
deposits, and D) Spearman rank correlation of Ki67 HS in the primary tumour and in the 
metastatic deposits in axillary LN.   
 
Tables 
  
Table 1: Ki67 Heterogeneity scores (Hes) for each of the full-face sections from 
different tumour quadrants of the studied series.   
 
 Range Mean Median 
Hes Quadrant  1 4 - 55 25.38 25 
Hes  Quadrant  2 1-  60 24.11 20 
Hes  Quadrant  3 3 - 70 25.49 20 
Hes  Quadrant  4 3 – 60 24.71 25 
 
 
 
 
 
  
Table 2: Levene’s F test for homogeneity of variance showing multiple and pairwise 
comparisons of coefficient of variation (CVAR) of HS, AS, and LS of Ki67 scores in the 
four quadrants of each of the studied case  
 
SCORE Pairwise 
Comparison  
S Error Significance, P 
CVAR HS 4 Q CVAR AS 4 Q 0.03711 0.835 
CVAR LS 4 Q 0.03711 0.002 
CVAR AS 4 Q CVAR LS 4 Q 0.03711 0.014 
 
 
 
Table 3: Statistical associations between Ki67 HS and AS and the clinicopathological 
parameters of the studied series:  
 
Parameter 
Quadrant1  
Significance 
P (test) 
Quadrant2 
Significance 
P (test)   
Quadrant3 
Significance 
P (test) 
Quadrant4  
Significance 
P (test) 
HS AS HS AS HS AS HS AS 
Age*      0.641 
(347.5) 
0.845 
(363.5) 
0.520 
(413.0) 
0.492 
(415.5) 
0.926 
(380.5) 
0.721 
(396.0) 
0.461 
(129.0) 
0.731 
(141.0) 
Menopausal 
Status* 
0.813 
(363.0) 
0.993 
(377.5) 
0.384 
(428.5) 
0.393 
(427.5) 
0.685 
(401.0) 
0.559 
(411.5) 
0.782 
(144.0) 
0.935 
156.0) 
Tumour 
Grade** 
< 0.001 
(25.5) 
< 0.001 
(23.4) 
< 0.001 
(25.5) 
< 0.001 
(24.3) 
< 0.001 
(27.5) 
< 0.001 
(27.5) 
< 0.001 
(21.8) 
< 0.001 
(25.3) 
Pleomorphism* < 0.001 
(498.0) 
< 0.001 
504.0) 
< 0.001 
(480.0) 
< 0.001 
(476.5) 
< 0.001 
(492.5 
< 0.001 
(498.0) 
< 0.001 
(218.5) 
< 0.001 
(221.0) 
Tubule 
Formation*  
0.227 
(377.0) 
0.244 
(374.5) 
0.246 
(374.5) 
0.212 
(379.0) 
0.089 
(403.5) 
0.202 
(380.5) 
0.299 
(161.5) 
0.268 
(163.5) 
Mitotic 
Figures**              
< 0.001 
(36.5) 
< 0.001 
(34.4) 
< 0.001 
(37.7) 
< 0.001 
(35.1) 
< 0.001 
(36.6) 
< 0.001 
(36.5) 
< 0.001 
(21.8) 
< 0.001 
(25.2) 
Tumour Size*          0.433 
(327.5) 
0.425 
(328.0) 
0.416 
(329.0) 
0.304 
(340.0) 
0.485 
(323.0) 
0.691 
(307.5) 
0.614 
(110.5) 
0.732 
(106.5) 
Axillary Nodal 
Stage**         
0.501 
(1.4) 
0.590 
(1.1) 
0.494 
(1.4) 
0.524 
(1.2) 
0.792 
(0.5) 
0.706 
(0.7) 
0.708 
(0.7) 
0.517 
(1.3) 
NPI**    0.094 
(4.7) 
0.099 
(4.6) 
0.071 
(5.3) 
0.063 
(5.5) 
0.056 
(5.7) 
0.136 
(3.9) 
0.064 
(5.5) 
0.055 
(5.7) 
Histological 
tumour type** 
0.001 
(18.7) 
0.001 
(19.1) 
0.002 
(17.1) 
0.003 
(16.6) 
0.004 
(15.2) 
0.004 
(15.4) 
0.042 
(8.2) 
0.051 
(7.7) 
LVI*     0.354 
(404.5) 
0.451 
(394.5) 
0.427 
(397.0) 
0.646 
(378.0) 
0.426 
(397.0) 
0.665 
(376.5) 
0.106 
(192.0) 
0.306 
(174.0) 
ER status*        
         
0.001 
(141.5) 
0.001 
(135.5) 
0.004 
(164.5) 
0.012 
(185.0) 
0.002 
(154.0) 
0.006 
(173.5) 
< 0.001 
(23.0) 
< 0.001 
(30.5) 
PR status* 
     
0.001 
(186.0) 
0.001 
(182.0) 
0.001 
(185.5) 
0.002 
(192.0) 
0.002 
(192.5) 
0.003 
(199.0) 
< 0.001 
(31.0) 
< 0.001 
(37.0) 
HER2 status* 0.006 
(10.1) 
0.018 
(8.1) 
0.001 
(13.3) 
0.005 
(10.4) 
0.004 
(10.8) 
0.011 
(9.1) 
0.013 
(8.6) 
0.008 
(9.6) 
Molecular 
Subtype**      
< 0.001 
(16.7) 
< 0.001 
(15.6) 
0.001 
(15.1) 
0.002 
(12.2) 
0.001 
(14.0) 
0.005 
(10.6) 
< 0.001 
(16.2) 
< 0.001 
(16.2) 
 
AS = Average score, HS = Hot spot score. * Mann-Whitney U test, ** Kruskal-Wallis test.    
Table 4: Classification of Ki67 stained sections from different tumour quadrants into 
low and High (at 14% cut-off point) for both the AS and HS.   
 
Quadrant 
Ki67 HS   
Total  
Low High  
AS Quadrant 1 
      Low  
      High  
Total 
 
11 
0 
11 
 
8 
36 
44 
 
19 
36 
55 
AS Quadrant2 
     Low 
     High  
Total 
 
7 
0 
7 
 
8 
40 
48 
 
15 
40 
55 
AS Quadrant3 
     Low 
     High  
Total 
 
8 
0 
8 
 
9 
38 
47 
 
17 
38 
55 
AS Quadrant4 
    Low 
    High  
Total 
 
5 
0 
 5 
 
5 
25 
30 
 
10 
25 
35 
 
Supplementary Table 1: Summary of patient demographics of the series used in this study   
Parameter Number (%) 
Age  
          ≤ 50 years  
          > 50 years   
 
25 (45.5) 
30 (54.5) 
Menopausal Status 
          Premenopausal  
          Postmenopausal 
 
26 (47.3) 
               29 (52.7) 
Tumour Grade  
          1 
          2 
          3 
 
3 (5.5) 
19 (34.5) 
                33 (60.0) 
Pleomorphisms         
            2 
            3 
 
14 (25.5) 
 41 (74.5) 
Tubule Formation  
         2 
         3 
 
16 (29.1) 
 39 (70.9) 
Mitotic Figures         
         1 
         2 
         3 
 
16 (29.1) 
10 (18.2) 
 29 (52.7) 
Tumour Size 
          ≤ 2 cm  
          > 2 cm  
 
14 (25.5) 
41 (74.5) 
Axillary Nodal Stage          
          1 
          2 
          3 
 
28 (50.9) 
20 (36.4) 
7 (12.7) 
Nottingham Prognostic Index (NPI) 
          Good NPI (<3.4) 
          Moderate NPI (3.41-5.4) 
          Poor NPI (≥5.4) 
 
4 (7.3) 
39 (70.9) 
12 (21.8) 
Histological tumour type 
          Ductal No Special Type (NST)  
          Lobular* 
          Mixed NST and Lobular 
 
44 (80.0) 
8 (14.5) 
3 (5.4) 
lymphovascular invasion (LVI)     
          Negative 
          Definite 
 
612 (65.2) 
327 (34.8) 
Distant Metastasis 
          Negative 
          Positive 
 
32 (58.2) 
23 (41.8) 
Survival (month) 
          Overall Survival: Median/mean (Range) 
          DFI : Median/mean (Range) 
 
145/131 (8-214) 
104/88 (10-214) 
ER status        
          ER  negative 
          ER  positive  
 
17 (30.9) 
38 (69.1) 
PR status 
          PR  negative 
          PR  positive  
 
26 (47.3) 
29 (52.7) 
HER2 status 
          HER2  negative  
          HER2  positive 
 
38 (74.5) 
13 (25.5) 
Molecular Subtype 
          Luminal 
          HER2 positive 
          Triple Negative 
 
34 (63.0) 
13 (24.1) 
7 (13.0) 
 
*Includes: classical lobular, alveolar lobular, solid lobular, tubule-lobular, and 
pleomorphic lobular.  
 




